financetom
Business
financetom
/
Business
/
Volkswagen in 'fair' talks with Washington on tariffs, says CEO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Volkswagen in 'fair' talks with Washington on tariffs, says CEO
May 29, 2025 10:58 PM

BERLIN (Reuters) -Volkswagen is holding "fair" and "constructive" talks with the United States government on tariffs and wants to make further investments in the country, CEO Oliver Blume told German newspaper Sueddeutsche Zeitung.

"So far, we have had absolutely fair, constructive discussions," Blume told the newspaper in an interview published on Friday. "I was in Washington myself and we have been in regular dialogue ever since."

Blume, who also leads Porsche AG as CEO, said Volkswagen's main contact in Washington was U.S. Commerce Secretary Howard Lutnick, adding he had agreed to keep any details of the discussions confidential.

Sources told Reuters earlier this week that Germany's carmakers, including Volkswagen, were in talks with Washington over a possible import tariff deal, seeking to use their U.S. investments and exports as leverage to soften any blow.

Asked what Blume was offering in the talks, he said: "The Volkswagen Group wants to invest further in the USA. We have a growth strategy."

Blume said the Volkswagen Group already employed over 20,000 people directly and over 55,000 people indirectly in the United States, also singling out a $5.8 billion investment in U.S. company Rivian .

"We would build on this with further, massive investments," Blume said, without elaborating.

(Writing by Friederike Heine and Christoph Steitz; Editing by Christian Schmollinger)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rivian overhauls CEO Scaringe's pay package to $4.55 billion, with new profit, stock-based award
Rivian overhauls CEO Scaringe's pay package to $4.55 billion, with new profit, stock-based award
Nov 7, 2025
* Scaringe's new pay plan linked to reduced stock price targets * New package also hinges on new profit, cash flow milestones * Rivian says aims to align CEO pay with shareholder returns * Scaringe's base salary doubled to $2 million Nov 7 (Reuters) - Rivian Automotive ( RIVN ) on Friday replaced Chief Executive RJ Scaringe's previous compensation plan...
Lazydays Announces Plan to Delist from Nasdaq
Lazydays Announces Plan to Delist from Nasdaq
Nov 7, 2025
TAMPA, Fla., Nov. 7, 2025 /PRNewswire/ -- Lazydays Holdings, Inc. ( GORV ) (NasdaqCM: GORV) today announced the Company's intention to delist its common stock (the Common Stock) from The Nasdaq Capital Market (Nasdaq). The Company anticipates the delisting will become effective on or about November 28, 2025, after the Company has completed requisite notifications to Nasdaq and the Securities...
BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Nov 7, 2025
MENLO PARK, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. ( BLLN ), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the closing of its upsized initial public offering of 5,233,765 shares of its Class A common stock, which includes the exercise in full of the underwriters’...
Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Nov 7, 2025
PALO ALTO, Calif., Nov. 7, 2025 /PRNewswire/ -- Evommune, Inc. (Evommune), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the closing of its initial public offering of 10,781,250 shares of common stock at an initial public offering price of $16.00 per share, which includes the exercise in full by the underwriters...
Copyright 2023-2026 - www.financetom.com All Rights Reserved